開開實業(600272.SH):擬與萬序公司、中野公司合資設立供應鏈管理公司
格隆匯 3 月 5日丨開開實業(600272.SH)公佈,公司全資子公司上海雷允上藥業西區有限公司(“雷允上”)擬與上海萬序健康科技有限公司(“萬序公司”)、上海中野醫療器械有限公司(“中野公司”)簽署合作協議,共同出資設立合資公司,擬定註冊資本為人民幣3000萬元整,首期實繳2000萬元,其中雷允上持有40%股權,萬序公司持有25%股權,中野公司持有35%股權。
雷允上擬與萬序公司、中野公司合資設立合資公司上海雷西精益供應鏈管理有限公司(“供應鏈管理公司”)(暫定名,具體以市場監督管理局核准的名稱為準),雷允上首期出資800萬元人民幣,持有40%股權。新設立的公司將通過發揮股東各方的資源優勢,服務於各級醫療機構供應鏈管理業務,培育新的經濟增長點,助推公司健康產業的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.